Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

AI-Driven Hip Exoskeleton Control for Diverse Users and Walking Tasks

10 de noviembre de 2026 actualizado por: Inseung Kang, Carnegie Mellon University

AI-Driven Hip Exoskeleton Control Framework That Rapidly Generalizes to a Broad Range of Users and Real-World Locomotor Tasks

The goal of this clinical trial is to evaluate the feasibility of a prototype artificial intelligence (AI)-based controller for a lightweight hip exoskeleton across a broad range of users, including healthy younger adults (18-39 years) and older adults (65 years and older). The main questions it aims to answer are:

  • Can the AI-based controller accurately estimate gait phase in real time across younger and older adults?
  • How does hip exoskeleton assistance change walking energy cost, mechanics, and muscle activity?

Researchers will compare walking with powered hip exoskeleton assistance to walking without the exoskeleton and walking while wearing the exoskeleton with no assistance (zero torque).

Participants will:

  • Complete a short screening and frailty assessment
  • Walk on a treadmill under different conditions with and without the hip exoskeleton during 2 to 5 lab visits
  • Wear motion capture markers, muscle activity (EMG) sensors, and a mask that measures breathing to estimate energy use

Descripción general del estudio

Estado

Reclutamiento

Descripción detallada

This study is funded by the National Institute of Biomedical Imaging and Bioengineering (R21EB037268) and conducted at the University of Texas at Austin in collaboration with Carnegie Mellon University. The CMU Hip Exoskeleton is a research prototype with powered hip joints for flexion and extension (peak torque 18 Nm, total weight 3.5 kg). Its controller uses joint angle and user-state estimates to command assistive torque, limited to less than 0.2 Nm/kg (at most about 30% of typical biological hip moments during walking), so it supplements rather than overrides the user's own muscle effort.

During each visit, participants walk on a force-instrumented treadmill at 1.25 m/s with safety harness and handrails. Researchers record whole-body motion capture, ground reaction forces, inertial measurement unit data, lower-limb electromyography, and metabolic energy expenditure via open-circuit indirect calorimetry. Walking conditions include no exoskeleton, exoskeleton worn with zero torque, and powered exoskeleton assistance. Outcomes will be compared across conditions and between younger and older adults using repeated-measures statistical analysis.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

16

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

    • Texas
      • Austin, Texas, Estados Unidos, 78712
        • Reclutamiento
        • University of Texas at Austin
        • Contacto:
        • Contacto:
        • Investigador principal:
          • Owen Beck, PhD

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

Sí

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Age 18 to 39 years (younger adult group) or 65 years and older (older adult group)
  • Willing and able to provide informed consent
  • Able to walk independently without assistance
  • No known cardiovascular, metabolic, or renal disease, and no signs or symptoms suggestive of such disease
  • Cleared for light- to moderate-intensity exercise without the need for medical clearance under American College of Sports Medicine (ACSM) preparticipation screening guidelines

Exclusion Criteria:

  • Age 40 to 64 years
  • Leg surgery within the past 5 years
  • Orthopedic disability that could impair movement or limit participation in the exercise protocol
  • Neurologic disorder that may affect neuromuscular function or gait (e.g., stroke, Parkinson's disease, peripheral neuropathy, traumatic brain injury)
  • Known metabolic or cardiovascular disease (hypertension alone is not exclusionary), or requiring medical clearance under ACSM guidelines without having obtained it
  • Metal implants in the lower extremities, cardiac pacemaker, or other implanted electronic device
  • Pregnancy
  • History of seizure disorder or fainting (syncope)

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Viabilidad del dispositivo
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Hip Exoskeleton Walking

Healthy younger adults (18-39 years) and older adults (65+ years) walk on an instrumented treadmill under multiple conditions across 2-5 lab visits: no exoskeleton, wearing the CMU Hip Exoskeleton with zero torque, and with powered assistance from the AI-driven hip exoskeleton controller (assistance limited to <0.2 Nm/kg). The primary objective is to evaluate real-time gait phase estimation accuracy of the prototype controller across users; metabolic cost, biomechanics, and muscle activity are recorded as secondary measures.

A lightweight (3.5 kg) research hip exoskeleton developed at Carnegie Mellon University with powered hip flexion/extension joints, a backpack-mounted computer and battery, and thigh and waist interfaces secured with straps. An AI-driven controller estimates the user's gait state from joint angle and wearable sensor data and commands assistive hip torque in real time, limited to <0.2 Nm/kg (peak device torque 18 Nm). Participants walk on a treadmill with powered assistance, with the device worn at zero torque, and without the device. The device was determined by the UT Austin IRB to be a non-significant risk device.

Otros nombres:
  • CMU Hip Exoskeleton

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Gait Phase Estimation Error of the AI-Driven Hip Exoskeleton Controller
Periodo de tiempo: Day 1

Root-mean-square error (RMSE) between the controller's real-time gait phase estimate and ground-truth gait phase derived from force-instrumented treadmill data during powered hip exoskeleton walking, reported as percent of the gait cycle (%). Used to evaluate feasibility of the prototype controller across younger and older adult users.

Day 1

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Net Metabolic Power During Powered Hip Exoskeleton Walking
Periodo de tiempo: Day 1

Net metabolic power (W/kg), measured by open-circuit indirect calorimetry with resting value subtracted, during treadmill walking at 1.25 m/s with powered hip exoskeleton assistance.

Day 1
Peak Hip Joint Moment During Powered Hip Exoskeleton Walking
Periodo de tiempo: Day 1

Peak biological hip extension moment (Nm/kg), computed from motion capture and force-instrumented treadmill data, during treadmill walking with powered hip exoskeleton assistance.

Day 1
Lower-Limb Muscle Activity During Powered Hip Exoskeleton Walking
Periodo de tiempo: Day 1

Average electromyography (EMG) amplitude normalized to maximum voluntary contraction (%MVC), averaged across eight recorded lower-limb muscles, during treadmill walking with powered hip exoskeleton assistance.

Day 1

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Inseung Kang, PhD, Carnegie Mellon University

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

6 de agosto de 2026

Finalización primaria (Estimado)

31 de agosto de 2027

Finalización del estudio (Estimado)

31 de enero de 2028

Fechas de registro del estudio

Enviado por primera vez

3 de noviembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

10 de noviembre de 2026

Publicado por primera vez (Actual)

16 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

16 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

10 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • STUDY2026_00000477
  • R21EB037268 (Subvención/contrato del NIH de EE. UU.)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

De-identified individual participant data underlying published results will be shared, including biomechanics (motion capture, ground reaction forces), electromyography, metabolic, and exoskeleton sensor/controller data, along with participant characteristics (age group, sex, height, mass). Identifiable information, including video recordings, will not be shared.

Marco de tiempo para compartir IPD

Data will be made available no later than the time of associated publication or the end of the award period, whichever comes first, and will remain available for at least 5 years.

Criterios de acceso compartido de IPD

De-identified data and supporting information will be deposited in a public data repository and made openly available to researchers without restriction, subject to the repository's terms of use.

Tipo de información de apoyo para compartir IPD

  • PROTOCOLO DE ESTUDIO
  • CÓDIGO_ANALÍTICO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

Sí

producto fabricado y exportado desde los EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir